Obstetrics & Gynecology

Suvemcitug plus chemotherapy improves PFS and OS in platinum-resistant ovarian cancer

In SCORES, 421 women with platinum-resistant recurrent ovarian cancer were randomized 2:1 to chemotherapy plus suvemcitug versus chemotherapy plus placebo. Median PFS improved from 2.7 months with placebo to 5.5 months with suvemcitug (HR 0.46, 95% CI 0.35–0.60; P < 0.001). Median OS increased from 14.0 to 15.3 months (HR 0.77, 95% CI 0.60–0.99; P = 0.03), indicating a modest survival gain. About half had prior antiangiogenic and PARP inhibitor exposure, suggesting benefit in heavily pretreated populations. 1

Simple hysterectomy matches radical hysterectomy outcomes with less urinary morbidity in early cervical cancer

This SHAPE trial analysis compared simple versus radical hysterectomy in very low-risk and higher-risk early-stage cervical cancer groups. In the very low-risk Conservative group (n = 107), no recurrences occurred in either arm over 4.5 years’ median follow-up. In the broader Liberal group (n = 575), simple hysterectomy had similar 3-year pelvic and extrapelvic RFS, overall RFS, and OS as radical hysterectomy. Multivariable analyses showed simple hysterectomy was not associated with higher recurrence or mortality; absence of residual tumor predicted lower recurrence. 2

Bivalent HPV-16/18 vaccine reshapes high-risk HPV lesion patterns over 10 years

This 10-year follow-up of a bivalent HPV-16/18 vaccine trial evaluated high-risk HPV incidence, clearance, and progression in women aged 18–45 years. Vaccination substantially reduced HPV-16/18–associated lesions (HR 0.12; p = 0.0041) by lowering incident infections and enhancing clearance of breakthrough infections. Vaccinated women had higher clearance (98.5% vs 93.8%) and lower progression (1.5% vs 6.2%) of HPV-16/18 infections. Conversely, HPV-52–associated lesions were more common in vaccine recipients (HR 3.06; p = 0.0303), driven by reduced clearance and increased progression rather than incidence. 3

ACOG outlines structured evaluation of positive hCG in nonpregnant patients without malignancy

This ACOG Clinical Consensus addresses evaluation of persistently positive hCG in nonpregnant patients without known gynecologic malignancy. It highlights that misinterpreted hCG elevations can lead to unnecessary invasive procedures and even chemotherapy. The guideline recommends a stepwise framework starting with careful evaluation for intrauterine and ectopic pregnancy. It then advises appropriate retesting and targeted investigations to differentiate assay interference, pituitary, and other nonmalignant sources. 4